Professor Alyn Morice

Professor Alyn Morice

Foundation Chair and Professor of Respiratory Medicine

Faculty and Department

  • Faculty of Health Sciences
  • Hull York Medical School

Summary

Professor Morice is Head of Respiratory Medicine at HYMS, based at the University of Hull. He is also an Honorary Consultant Physician at Hull & East Yorkshire Hospitals NHS Trust. Professor Morice specialises in the diagnosis and treatment of cough, and runs the Hull Cough Clinic. He also runs the Hull Respiratory Clinical Trials Unit, specialising in the treatment of asthma and COPD.

The Hull Cough Clinic is one of the largest centres within Europe, with an international pattern of referral. Unique investigational strategies provide diagnosis and treatment advances, which are incorporated into national and international guideline documents.

Professor Morice has led the European Respiratory Society and British Thoracic Society Taskforces on Cough.

Recent outputs

View more outputs

Journal Article

Rhinovirus-16 increases ATP release in A549 cells without concomitant increase in production

Atkinson, S. K., Morice, A. H., & Sadofsky, L. R. (2020). Rhinovirus-16 increases ATP release in A549 cells without concomitant increase in production. ERJ Open Research, 6(4), https://doi.org/10.1183/23120541.00159-2020

Azithromycin for sarcoidosis cough: an open label exploratory clinical trial

Fraser, S. D., Thackray-Nocera, S., Shepherd, M., Flockton, R., Wright, C., Sheedy, W., …Hart, S. P. (2020). Azithromycin for sarcoidosis cough: an open label exploratory clinical trial. ERJ Open Research, 6(4), https://doi.org/10.1183/23120541.00534-2020

Cough persistence in adults with chronic cough: a 4-year retrospective cohort study

Kang, S. Y., Song, W. J., Won, H. K., Chung, S. J., Kim, J. Y., Park, H. W., … Cho, S. (2020). Cough persistence in adults with chronic cough: a 4-year retrospective cohort study. Allergology International, 69(4), 588-593. https://doi.org/10.1016/j.alit.2020.03.012

Gefapixant, a P2X3 receptor antagonist, for the treatment of refractory or unexplained chronic cough: a randomised, double-blind, controlled, parallel-group, phase 2b trial

Smith, J. A., Kitt, M. M., Morice, A., Birring, S. S., McGarvey, L. P., Sher, M. R., …Iyer, V. (2020). Gefapixant, a P2X3 receptor antagonist, for the treatment of refractory or unexplained chronic cough: a randomised, double-blind, controlled, parallel-group, phase 2b trial. The lancet. Respiratory medicine, 8(8), 775-785. https://doi.org/10.1016/S2213-2600%2819%2930471-0

Characterisation of a New Human Alveolar Macrophage-Like Cell Line (Daisy)

Sadofsky, L. R., Hayman, Y. A., Vance, J., Cervantes, J. L., Fraser, S. D., Wilkinson, H. N., …Morice, A. H. (2019). Characterisation of a New Human Alveolar Macrophage-Like Cell Line (Daisy). Lung, 197(6), 687-698. https://doi.org/10.1007/s00408-019-00288-3

Project

Funder

Grant

Started

Status

Project

AX-8 Clinical Research Collaboration

Funder

Hull University Teaching Hospitals NHS Trust

Grant

£21,285.00

Started

1 June 2016

Status

Complete

Project

VOLCANO-2: A double-blind, placebo controlled study of the efficacy and safety of three doses of Orvepitant in subjects with chronic refractory cough

Funder

Hull University Teaching Hospitals NHS Trust

Grant

£42,493.00

Started

1 August 2017

Status

Complete

Project

Lavolta - A phase III, randomized, double-blind, placebo-controlled study to assess the efficacy and safety of

Funder

Hull University Teaching Hospitals NHS Trust

Grant

£19,047.00

Started

18 May 2014

Status

Complete

Project

OSPREY: An Observational Study of the Phenotype and pRescribing in East Yorkshire and its relevance to the introduction of new prescribing guidelines for airways disease.

Funder

AstraZeneca UK Limited

Grant

£163,413.00

Started

1 October 2016

Status

Complete

Project

Orbit-4: A multi-centre, randomised, double-blind, placebo-controlled study to evaluate the safety and efficacy of Pulmaquin in the management of chronic lung infections with pseudomonas aeruginosa in subjects with non-cystic fibrosis bronchiectasis, including 28

Funder

Aradigm Corporation

Grant

£30,144.00

Started

31 October 2014

Status

Complete

Project

TUF: The Utility of FeNo in the differential diagnosis of chronic cough

Funder

Aerocrine AB

Grant

£30,000.00

Started

2 November 2015

Status

Complete

Project

Development Costs: A Study to Assess the Effect of AF-219 on Cough Reflex Sensitivity in Both Healthy and Chronic Cough Subjects

Funder

Afferent Pharmaceuticals Inc

Grant

£62,207.00

Started

5 October 2015

Status

Complete

Project

AFFERENT14: A Study to Assess the Effect of AF-219 on Cough Reflex Sensitivity in Both Healthy and Chronic Cough Subjects

Funder

Afferent Pharmaceuticals Inc

Grant

£140,667.00

Started

5 October 2015

Status

Complete

Project

AFFERENT12: AF219-012: A 12 week Study to assess the Efficacy and tolerability of AF 219 in subjects with treatm

Funder

Afferent Pharmaceuticals Inc

Grant

£22,020.00

Started

1 March 2016

Status

Complete

Project

Proof of Concept study (POC) to investigate the effect of ambroxol hydrochloride (20mg lozenges) on the cough reflex in patients with acute upper respiratory tract infection

Funder

Sanofi Aventis

Grant

£27,342.00

Started

1 October 2017

Status

Complete

Project

TUSSIX: MTI-110 - A randomized, double-blind, placebo-controlled study of the efficacy, safety, and tolerability of Serlopitant for the treatment of refractory chronic cough

Funder

Hull University Teaching Hospitals NHS Trust

Grant

£16,546.00

Started

1 December 2017

Status

Complete